Daniel R. Chevallard Viracta Therapeutics, Inc. (VIRX) insider trading activity

Daniel R. Chevallard is CFO and COO of Viracta Therapeutics, Inc.. Currently has a direct ownership of 102,306 shares of VIRX, which is worth approximately $20,461. The most recent transaction as insider was on Feb 27, 2024, when has been sold 3,405 shares (Common Stock) at a price of $0.73 per share, resulting in proceeds of $2,485. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 102K

0% 3M change

6.96% 12M change

Total Value Held $20,461

Daniel R. Chevallard Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 27 2024	SELL Open market or private sale	$2,485 $0.73 p/Share	3,405 Reduced 3.22%	102,306 Common Stock
Feb 25 2024	BUY Exercise of conversion of derivative security	-	6,889 Added 6.12%	105,711 Common Stock
Nov 28 2023	SELL Open market or private sale	$1,860 $0.5 p/Share	3,720 Reduced 3.63%	98,822 Common Stock
Nov 25 2023	BUY Exercise of conversion of derivative security	-	6,889 Added 6.3%	102,542 Common Stock
Aug 28 2023	SELL Open market or private sale	$5,092 $1.45 p/Share	3,512 Reduced 3.54%	95,653 Common Stock
Aug 25 2023	BUY Exercise of conversion of derivative security	-	6,888 Added 6.49%	99,165 Common Stock
May 25 2023	SELL Open market or private sale	$5,161 $1.42 p/Share	3,635 Reduced 3.79%	92,277 Common Stock
May 25 2023	BUY Exercise of conversion of derivative security	-	6,889 Added 6.7%	95,912 Common Stock
Feb 27 2023	SELL Open market or private sale	$6,046 $1.68 p/Share	3,599 Reduced 3.89%	89,023 Common Stock
Feb 25 2023	BUY Exercise of conversion of derivative security	-	6,889 Added 6.92%	92,622 Common Stock
Nov 28 2022	SELL Open market or private sale	$9,607 $2.72 p/Share	3,532 Reduced 3.96%	85,733 Common Stock
Nov 25 2022	BUY Exercise of conversion of derivative security	-	6,889 Added 7.16%	89,265 Common Stock
Aug 26 2022	SELL Open market or private sale	$14,693 $4.02 p/Share	3,655 Reduced 4.25%	82,376 Common Stock
Aug 25 2022	BUY Exercise of conversion of derivative security	-	6,889 Added 7.41%	86,031 Common Stock
May 26 2022	SELL Open market or private sale	$6,832 $1.9 p/Share	3,596 Reduced 4.35%	79,142 Common Stock
May 25 2022	BUY Exercise of conversion of derivative security	-	6,889 Added 7.69%	82,738 Common Stock
Feb 28 2022	SELL Open market or private sale	$11,114 $2.78 p/Share	3,998 Reduced 5.01%	75,849 Common Stock
Feb 25 2022	BUY Exercise of conversion of derivative security	-	6,889 Added 7.94%	79,847 Common Stock
Nov 29 2021	SELL Open market or private sale	$20,847 $4.82 p/Share	4,325 Reduced 5.6%	72,958 Common Stock
Nov 26 2021	SELL Open market or private sale	$15,619 $4.8 p/Share	3,254 Reduced 4.04%	77,283 Common Stock
Nov 25 2021	BUY Exercise of conversion of derivative security	-	13,777 Added 14.61%	80,537 Common Stock
Sep 28 2021	BUY Exercise of conversion of derivative security	$9,000 $0.9 p/Share	10,000 Added 13.03%	66,760 Common Stock
May 28 2021	BUY Exercise of conversion of derivative security	$10,800 $0.9 p/Share	12,000 Added 17.45%	56,760 Common Stock

Also insider at

GRPH

Graphite Bio, Inc. Healthcare

Chief Financial Officer

DRC